← XNCR: big moves and long-term fundamentals中文

Xencor: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 16, 2026 · Reflects: 10-K FY2025 and the 10-Q for Q3 2026

This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 16, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026.

Xencor engineers antibodies and sells no drugs of its own. It earns royalties (payments based on partners’ drug sales) and milestone payments (triggered by set development, regulatory or sales events) from partners that license its XmAb technology, and reports one segment. In 2025 revenue was $125.6M: royalties $80.3M (64%) and milestones $45.3M (36%). The royalties come mainly from Ultomiris (Alexion, part of AstraZeneca) and Monjuvi (Incyte). Almost all 2025 royalty revenue ($80.3M) was non-cash: Xencor sold those royalties to OMERS, a Canadian pension fund, in 2023, so they are paid to OMERS. In the first nine months of 2026, revenue was $172.3M, mostly one-off: $105.0M from settling a dispute with Alexion over US Ultomiris royalties, and milestones as partners’ drugs advanced. Its spending goes to its own drug candidates, led by XmAb819 (kidney cancer) and XmAb942 (ulcerative colitis).

Sources: 10-K FY2025, note 2 and cash-flow statement; 10-Q Q3 2026, note 2.

2. Story so far

Last updated Nov 16, 2026. Reflects filings through Nov 4, 2026.

In short: Xencor has paid for its own pipeline mainly with partner payments, a 2023 sale of royalty rights and a 2024 share sale. In 2026 a dispute over US Ultomiris royalties ended in a $105M settlement, partners’ drugs that use its technology moved into late-stage trials, and its kidney cancer drug XmAb819 moved toward one of its own.

| Oct 1, 2021 | Second Janssen (Johnson & Johnson) deal: $100M upfront, plus a $25M share purchase at $33.42 a share | 8-K | | Nov 3, 2023 | ★ Sells Ultomiris and Monjuvi royalty rights to OMERS for $192.5M and $22.5M upfront | 8-K | | Sep 9–12, 2024 | ★ Outlines autoimmune programmes (plamotamab, XmAb657, XmAb942) and raises $201.3M gross from shares and pre-funded warrants (rights to shares for $0.01 each) | 8-K, closing release | | Feb 11–27, 2025 | Restates 2023: the royalty sale becomes debt, and 2023 operating cash flow was overstated by $163.0M. KPMG replaces RSM as auditor | 8-K, 8-K | | Feb–Jun 2025 | $37.5M of Incyte milestones as the US Food and Drug Administration (FDA) accepts, then approves, a new Monjuvi application | 10-Q Q2 2026, note 2 | | Oct 24, 2025 | First XmAb819 update: tumors shrank in 25% of 20 patients in the target dose range | Presentation | | Mar 4, 2026 | Alexion says it owes no more US Ultomiris royalties; Xencor had expected $100–120M of them through 2028. Genentech ends their collaboration the same day (effective Sep 4, 2026) | Release, 8-K | | Jul 2026 | Merus drops its patent suit; Xencor receives $7.0M | 10-Q, note 7 | | Jul 29, 2026 | ★ Settles with Alexion for $105M in two $52.5M payments; Alexion owes no more US Ultomiris royalties | 8-K | | Oct 25, 2026 | ★ XmAb819 shrinks tumors in 5 of 11 patients (45.5%) at the 400 mcg/kg dose chosen for late-stage trials; cash runway guide moves to “into 2029” | Release, 8-K | | Oct 26, 2026 | Start of our coverage: Xencor jumps 16% as its kidney cancer drug shrinks tumors in early trial | WhyMyStockMoved | | Aug 2026 | Astellas starts a Phase 3 trial of ASP2138, a stomach cancer drug built with Xencor’s technology; Xencor receives a $25.0M milestone | 10-Q Q3 2026, note 2 | | Nov 4, 2026 | Q3: revenue $116.5M and net income $39.4M, mostly from the Alexion settlement and the Astellas milestone; year-end cash guide raised to $480–500M. Stock rose 14.3% that day, using closes reported by Yahoo Finance ($30.64 on Nov 3; $35.03 on Nov 4; our calculation1) | Q3 release |

3. Latest quarter: did the story change?

Last updated Nov 16, 2026. Reflects Q3 2026 (10-Q and release, Nov 4, 2026).

Bottom line: Q3 revenue more than doubled on one-off items, the rest of the Alexion settlement and a $25.0M Astellas milestone, giving Xencor a $39.4M profit for the quarter. It raised its year-end cash guide and keeps its runway “into 2029”, while research spending rose again. The 10-Q adds that, under the settlement, Xencor must fund certain shortfalls in the Ultomiris royalties it sold to OMERS.

Driver Last quarter → this quarter Management: before → now Signal
Revenue Q2 $51.2M → Q3 $116.5M, including $77.4M of Alexion settlement revenue and the $25.0M Astellas milestone No revenue guide; $77.4M of the settlement to be booked in Q3 (Aug 5) → booked (Nov 4) Better
Cash outlook (cash, equivalents and marketable debt securities) Jun 30 $486.4M → Sep 30 $555.7M, after the first $52.5M Alexion payment and $66.9M from selling Zenas shares Year-end 2026 $420–440M, runway “through 2028” (Aug 5) → $480–500M, runway “into 2029” (Oct 25 and Nov 4) Better
Research and development spending Q2 $71.9M → Q3 $84.3M (+55% vs Q3 2025) No expense guide; costs “are expected to increase as programs advance” (10-Q, Nov 4) Watch
XmAb819 (kidney cancer) Dose expansion under way (Aug 5) → 400 mcg/kg chosen as the proposed Phase 3 dose; tumours shrank in 5 of 11 evaluable patients (45.5%) (Oct 25, repeated Nov 4) Registration-enabling study “during 2027” (Aug 5) → FDA talks on a potential accelerated approval in 1H 2027; Phase 3 against tivozanib by end of 2027, subject to regulatory feedback (Oct 25 and Nov 4) Watch
Partner programmes Amgen’s xaluritamig in Phase 3; Zenas’s obexelimab filed in the US (May) → Astellas Phase 3 started (Aug); Amgen’s XALute enrolled; obexelimab filed in Japan and Europe Milestones from partners: $10.0M in Q2 → $29.0M in Q3 (Astellas $25.0M, Zenas $2.5M, Incyte $1.5M) (10-Q, note 2) Better

Sources: Q2 release, Q3 release, 10-Q Q3 2026, Oct 25 release.

Unresolved questions: whether XmAb819’s response rate holds in more patients at the chosen dose (more data in 1H 2027), and how much the OMERS shortfall funding will cost; the 10-Q gives no amount beyond $5.0M of cash set aside at Sep 30.

4. Buybacks vs real dilution (5 years)

Last updated Nov 16, 2026. Reflects the equity statements in the 10-K FY2023, 10-K FY2025 and 10-Q Q3 2026.

Dilution in one line: shares outstanding plus pre-funded warrants rose 32% from Dec 31, 2020 to Sep 30, 2026, about 5.0% a year compounded. If you owned 1% of Xencor at the end of 2020, you would own about 0.76% today without buying more (our calculation)2. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2020 to Sep 30, 2026FY2021 +2.6%, FY2022 +1.1%, FY2023 +1.7%, FY2024 +20.2%, FY2025 +2.2%, 9M 2026 +2.0%. Total +32.1% since Dec 31, 2020.0%+10%+20%+30%+40%FY2021: +2.6% in the period; +2.6% since Dec 31, 2020+2.6%FY2021FY2022: +1.1% in the period; +3.7% since Dec 31, 2020+1.1%FY2022FY2023: +1.7% in the period; +5.4% since Dec 31, 2020+1.7%FY2023FY2024: +20.2% in the period; +26.7% since Dec 31, 2020+20.2%FY2024FY2025: +2.2% in the period; +29.5% since Dec 31, 2020+2.2%FY20259M 2026 (part year): +2.0% in the period; +32.1% since Dec 31, 2020+2.0%9M 2026+32.1%since Dec 31, 2020

Change in the period Total since Dec 31, 2020 Part year

Shares outstanding at period end (all classes): 57.9M on Dec 31, 2020, 76.5M on Sep 30, 2026, +32.1% (our calculation). A bar below zero means the count fell (net buybacks).

Shares outstanding plus pre-funded warrants (exercisable at $0.01), from the author's bridge (10-K and 10-Q equity statements); pre-funded warrants have no standard XBRL tag.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
9M 2026 (Sep 30, 2026)76.5M+2.0%———
FY2025 (Dec 31, 2025)75.0M+2.2%—$43M34%
FY2024 (Dec 31, 2024)73.3M+20.2%—$53M48%
FY2023 (Dec 31, 2023)61.0M+1.7%—$54M31%
FY2022 (Dec 31, 2022)60.0M+1.1%—$49M30%
FY2021 (Dec 31, 2021)59.4M+2.6%—$37M13%
FY2020 (Dec 31, 2020)57.9M——$32M26%

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

How we calculated this

We count pre-funded warrants (1.70M at Sep 30, 2026; the equity statements show none exercised after January) as shares: they cost $0.01 to exercise, and Xencor counts them in its loss per share.

Bridge (millions of shares) 2021 2022 2023 2024 2025 9M 2026 Total
Start of period 57.87 59.36 60.00 61.00 73.35 74.96 57.87
Stock pay and options (equity plans) 0.73 0.64 1.00 1.16 1.62 1.50 6.65
Share sales for cash (incl. pre-funded warrants) 0.75 – – 11.18 – – 11.93
Acquisitions, convertible notes – – – – – – –
Buybacks 0 0 0 0 0 0 0
End of period 59.36 60.00 61.00 73.35 74.96 76.46 76.46

In January 2026, 1.39M pre-funded warrants were exercised into common shares, which leaves the total unchanged. Displayed figures may not sum exactly because of rounding.

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2021 — — — 0.75M $33.42 $25.0M 8-K, Oct 1, 2021: 748,062 shares to Johnson & Johnson Innovation at a 30-day average price
2022 — — — — — — 10-K FY2023 equity statement
2023 — — — — — — 10-K FY2025 equity statement
2024 — — — 11.18M $18.00 (our calculation) $201.3M Closing release, Sep 12, 2024: 8.09M shares at $18.00 and 3.09M pre-funded warrants at $17.99, gross
2025 — — — — — — 10-K FY2025
2026 to date (Jan 1–Sep 30) — — — — — — 10-Q Q3 2026: no shares issued under the at-the-market agreement

Xencor has sold shares for cash twice in the period, in 2021 and in the 2024 offering, and has bought none back. The 2024 average is derived (our calculation)3.

Basis and details
  • No stock splits in the period, so figures are as reported. Raised is gross, before fees.
  • The equity statements show no buybacks; employee plan shares are excluded from sales.
  • For reference, Yahoo Finance reported a closing price of $37.09 on Nov 13, 2026 (price history).
Stock-based pay 2021 2022 2023 2024 2025 9M 2026
$M 37.0 48.9 53.8 53.3 43.2 28.2
% of revenue (our calculation)4 13% 30% 31% 48% 34% 16%

2023 revenue is the restated $174.6M (10-K FY2025).

9M 2026 revenue was lifted by the one-off Alexion settlement, so its stock-pay percentage is low.

5. Profit vs cash (latest FY and TTM)

Last updated Nov 16, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026.

Xencor loses money and burns cash, although one-off settlement and milestone payments narrowed both in the past year. It publishes no adjusted profit measure.

$M FY2025 Trailing twelve months (TTM) to Sep 30, 2026 (our calculation)5
Net loss −91.9 −117.9
Adjusted metric Not reported Not reported
Operating cash flow −135.1 −172.4
Capital spending −3.2 −4.1
Free cash flow (our calculation)6 −138.3 −176.4

Xencor’s cash burn differs from its loss mainly because of non-cash royalty and investment items. Grouped by what each means for future profit and cash (TTM unless stated):

Helps future profit or cash:

  • Changes in receivables reduced operating cash flow by $49.7M in the first nine months of 2026; receivables on the balance sheet rose $35.5M, including the second $52.5M Alexion payment: Booked as revenue in 2026; that cash is due in August 2027.

Hurts future profit or cash:

  • $45.8M of royalty revenue was non-cash ($80.3M in 2025), because OMERS receives those royalties: Shown as revenue, but the cash goes to OMERS; Monjuvi royalties flow to Xencor again since OMERS reached its cap in Q2 2026 (section 6).
  • Stock-based pay ($38.4M; $43.2M in 2025): Not a cash cost, but it is a cost in the loss and it adds shares (see section 4).
  • Non-cash interest on the royalty-sale debt ($21.1M; $31.9M in 2025): Lowers reported profit but uses no cash.

One-off / no lasting effect:

  • Operating cash flow includes $104.4M of one-off receipts: the first Alexion settlement payment ($52.5M), partner milestones ($44.8M), the Merus settlement ($7.0M) and an INmune licence-extension fee ($0.1M): Cash that does not repeat on its own; the cash path below leaves it out of usual spending.
  • Gains and losses on shareholdings, mainly Zenas BioPharma (+$87.1M of non-cash gains in 2025; −$18.7M in the first nine months of 2026): No cash until shares are sold; Xencor sold 2.1M Zenas shares for $66.9M in Q3 2026, which counts as investing cash flow.
The raw reconciling items
  • Non-cash royalty revenue: $80.3M in 2025, $45.8M TTM.
  • Stock-based pay: $43.2M in 2025, $38.4M TTM. Non-cash interest on the royalty-sale debt: $31.9M in 2025, $21.1M TTM.
  • Shareholdings: +$87.1M of unrealized gains and +$14.4M of realized gains in 2025; in the first nine months of 2026, −$9.3M from changes in value and −$9.3M of losses on sales.
  • Receivables: +$28.7M of cash in 2025 (including a $30.0M Amgen milestone collected in January 2025); −$49.7M in the first nine months of 2026.
  • One-off receipts in the 12 months to Sep 30, 2026 (10-Q Q3 2026, notes 2 and 7): Alexion $52.5M (August 2026); Astellas $25.0M (Q3 2026); Zenas $10.0M (Q2) and $2.5M (Q3); Merus $7.0M (July, booked against legal costs); Incyte $4.0M (collected January 2026) and $1.5M (Q3); Mabgeek $1.8M (earned in Q4 2025; collection in Q1 2026 is our inference from the receivables reconciliation); INmune licence-extension fee $0.1M (Q1).

Funding: how long without new money? (our calculation; as of Sep 30, 2026, the latest filed balance sheet)

  • Cash, cash equivalents and marketable debt securities of $555.7M covered about 2.0 years of usual spending of $280.8M a year, which leaves out one-off receipts (our calculation)7. Xencor says its existing cash, marketable securities and “certain potential milestone payments” will fund operations “into 2029” (10-Q Q3 2026), and it guides to $480–500M at the end of 2026 (Q3 release).
Funding details
  • The $555.7M is Xencor’s own measure. It excludes $27.0M of Zenas shares (1.0M shares at Sep 30) and $5.2M of restricted cash.
  • Debt and convertible notes due within 24 months: none. The $95.1M royalty-sale liability is repaid from royalties paid to OMERS, not from Xencor’s cash; but under the Alexion settlement Xencor must now fund certain shortfalls in Ultomiris royalties owed to OMERS, and it held $5.0M of restricted cash for this at Sep 30 (10-Q, note 2).
  • Undrawn credit lines: none disclosed.
  • At-the-market share-sale programme: a $200M agreement signed Feb 27, 2023, with no shares issued at Sep 30, 2026 (8-K, 10-Q); a prospectus supplement is needed before any sales.
  • Based on past cash flow; spending plans can change it.

Extends the runway:

  • The second Alexion settlement payment of $52.5M, due within 14 days after Jul 29, 2027 (8-K). It is already a known item in the cash path; there is no committed credit line or other undrawn financing.

Shortens the runway:

  • Funding of shortfalls in Ultomiris royalties owed to OMERS, amount not disclosed beyond the $5.0M set aside; not in the cash path.

Conditional:

  • The $200M at-the-market agreement, which needs a prospectus supplement and brings in cash only if Xencor sells shares.
  • Selling the remaining Zenas shares ($27.0M at Sep 30).
  • Partner milestones, which depend on partners’ progress: for example up to $225M from Amgen, $207.5M from Astellas and $447.5M from Zenas (Q3 release).

Cash path (our calculation; an illustration, not a forecast):

At the past rate and with known items, cash would fall below zero in Q4 2028; the company itself says its cash, marketable securities and certain potential milestone payments will fund operations into 2029 (10-Q Q3 2026).

Illustration, not a forecast.

Cash path: ending cash by quarter (illustration)Start $556M, Q4 2026 $486M, Q1 2027 $415M, Q2 2027 $345M, Q3 2027 $327M, Q4 2027 $257M, Q1 2028 $187M, Q2 2028 $117M, Q3 2028 $47M, Q4 2028 −$24M.Q4 2027: raising window (under a year of usual spending left)Q1 2028: raising window (under a year of usual spending left)Q2 2028: raising window (under a year of usual spending left)Q3 2028: raising window (under a year of usual spending left)Q4 2028: would need new money−$100M$0M$100M$200M$300M$400M$500M$600MStart: $556MQ4 2026: $486MQ1 2027: $415MQ2 2027: $345MQ3 2027: $327MQ4 2027: $257MQ1 2028: $187MQ2 2028: $117MQ3 2028: $47MQ4 2028: −$24MStartQ4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028Q3 2028Q4 2028Q3 2027: known item $53M (Second Alexion payment, due within 14 days after Jul 29, 2027 (8-K))1
  1. 1 · Q3 2027 · Second Alexion payment +$53M

Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money

Quarter Starting cash Usual spending Known items Ending cash Sources / notes
Q4 2026 +555.7 −70.2 0.0 +485.5
Q1 2027 +485.5 −70.2 0.0 +415.3
Q2 2027 +415.3 −70.2 0.0 +345.1
Q3 2027 +345.1 −70.2 +52.5 +327.3 Second Alexion payment, due within 14 days after Jul 29, 2027 (8-K)
Q4 2027 +327.3 −70.2 0.0 +257.1 Less than a year of usual spending left.
Q1 2028 +257.1 −70.2 0.0 +186.9 Less than a year of usual spending left.
Q2 2028 +186.9 −70.2 0.0 +116.7 Less than a year of usual spending left.
Q3 2028 +116.7 −70.2 0.0 +46.5 Less than a year of usual spending left.
Q4 2028 +46.5 −70.2 0.0 −23.7

Amounts in $M.

At the past rate and with known items, cash would fall below zero in Q4 2028; the company itself says its cash, marketable securities and certain potential milestone payments will fund operations into 2029 (10-Q Q3 2026). Our path counts no future milestones and assumes flat spending; with the past year’s one-off receipts left in, it would reach zero in Q1 2030 (our calculation)8. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.

What the cash path counts:

  • Usual spending: about −$70.2M a quarter, held flat, leaving out $104.4M of one-off receipts in the past year.
  • Known items: the second Alexion settlement payment of +$52.5M, due in Q3 2027.
How we calculated this

Usual spending is (trailing-12-month free cash flow − one-off receipts) ÷ 4 = (−$176.447M − $104.4M) ÷ 4 = −$70.21M a quarter, held flat9. The one-off receipts are the settlement and milestone payments listed under “The raw reconciling items” above; our rule removes them because together they exceed 20% of the trailing free cash flow. Calculations use unrounded amounts, and table values are rounded to $0.1M. Starting cash is Xencor’s cash, cash equivalents and marketable debt securities at Sep 30, 2026; the $27.0M of Zenas shares is not included (in our Oct 27 path it was). Lease payments are already in operating cash flow, so they are not added. Trailing-12-month capex ($4.1M) was in line with 2025 ($3.2M); Xencor has disclosed no capex plan. Not included: possible partner milestones and royalties, the OMERS shortfall funding (amount not disclosed) and any share sales.

6. Customer and contract exposure

Last updated Nov 16, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026.

Revenue depends on a few partners; the mix shifts with milestone timing and, in 2026, with the one-off Alexion settlement.

Share of revenue (our calculation)10 2023 2024 2025 9M 2026
Alexion (Ultomiris royalties and settlement) 37% 53% 56% 71%
Incyte (Monjuvi royalties, milestones) 5% 8% 41% 7%
Janssen 45% — — —
Amgen — 27% — —
Astellas — — — 15%
Zenas 6% — — 7%

Sources: 10-K FY2025, note 2 (2023 restated); 10-Q Q3 2026, note 2.

Alexion and Incyte supplied most revenue (about 97% of 2025 and 78% of the first nine months of 2026, our calculation)10, almost all of it royalties, the settlement and milestones that depend on partners’ sales and progress.

Alexion and Incyte share of Xencor revenue
Alexion, 2023: 37% of revenueAlexion, 202337%Alexion, 2024: 53% of revenueAlexion, 202453%Alexion, 2025: 56% of revenueAlexion, 202556%Alexion, 9M 2026: 71% of revenueAlexion, 9M 202671%Incyte, 2023: 5% of revenueIncyte, 20235%Incyte, 2024: 8% of revenueIncyte, 20248%Incyte, 2025: 41% of revenueIncyte, 202541%Incyte, 9M 2026: 7% of revenueIncyte, 9M 20267%
Show the data
Label Value Unit
Alexion, 2023 37 % of revenue
Alexion, 2024 53 % of revenue
Alexion, 2025 56 % of revenue
Alexion, 9M 2026 71 % of revenue
Incyte, 2023 5 % of revenue
Incyte, 2024 8 % of revenue
Incyte, 2025 41 % of revenue
Incyte, 9M 2026 7 % of revenue

Chart source11.

Partner and contract details
  • Two customers made up about 91% of receivables at Dec 31, 2025.
  • Alexion pays low-single-digit Ultomiris royalties, now ex-US only; US royalties ended with the $105.0M settlement. OMERS is entitled to up to $35M of them a year for 2026–28, then up to $12M a year, and Xencor must fund certain shortfalls (10-Q, note 2). In October 2026 the FDA granted Ultomiris accelerated approval in IgA nephropathy, a kidney disease.
  • Monjuvi royalties flow to Xencor again since OMERS reached its $29.3M cap in Q2 2026; Incyte’s first-line lymphoma filings for tafasitamab were accepted for review in Q2 2026.
  • Zenas licensed obexelimab: up to $447.5M in milestones, plus royalties from the mid-single digits to the mid-teens. The FDA’s target decision date is May 27, 2027, Zenas said (Zenas release, Aug 13, 2026); filings in Japan and Europe followed in Q3 and October.
  • Amgen’s xaluritamig is in two Phase 3 trials in prostate cancer; up to $225M in milestones, plus mid- to high-single-digit royalties.
  • Astellas’s ASP2138 is in Phase 3 in stomach cancer; up to $207.5M in milestones, plus royalties from the high single digits to the low double digits.
  • Genentech’s collaboration ended Sep 4, 2026 (8-K).

7. Xencor’s strategy for long-term growth

Last updated Nov 16, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and the Q3 release (Nov 4, 2026).

Xencor is trying to turn its antibody engineering into drugs of its own, starting with XmAb819 in kidney cancer, while partners’ drugs built on its technology bring in milestones and royalties. None of its own drugs is yet in a late-stage trial.

  • Pressures on the core business:
    • its royalty income is shrinking: Alexion no longer pays US Ultomiris royalties after the settlement, OMERS takes up to $35M a year of the ex-US ones for 2026–28, and Xencor must fund certain shortfalls in them (10-Q, note 2);
    • competition: the 10-K names Amgen, Genmab, Regeneron and Roche among companies with competing bispecific antibody platforms (antibodies designed to bind two different targets), and Merck, Roche, Sanofi and Teva among those testing antibodies against TL1A, a protein involved in inflammation, like XmAb942 in bowel disease (10-K FY2025);
    • patents: Merus dropped its patent suit in July 2026, but the 10-Q’s new risk factor notes that others may claim Xencor’s products infringe their patents (10-Q).
  • The strategy in management’s words: “We expect that the accelerating tempo of clinical development for XmAb819, and across our portfolio, may present multiple opportunities for continued momentum into the new year and throughout 2027”, and by the end of 2027 XmAb819 should be “the third XmAb 2+1 bispecific antibody to enter a potential registration-enabling study, following xaluritamig and ASP2138” (Bassil Dahiyat, CEO, Q3 release). Xencor also partners “selected programs to access complementary development and commercialization capabilities” (10-Q). The steps so far:
    • cancer: XmAb819 dose chosen for Phase 3; trials in other tumours that carry ENPP3 and with nivolumab are enrolling or planned; XmAb541 is now tested with XmAb808 after moderate results on its own;
    • autoimmune and inflammatory disease: a Phase 2b trial of XmAb942 in ulcerative colitis (main result in 2H 2027), XmAb412 in its first human study, and plamotamab and XmAb657, which deplete B cells, in Phase 1;
    • partners: Amgen (xaluritamig) and Astellas (ASP2138) have taken drugs built with Xencor’s 2+1 format into Phase 3, and Zenas has filed obexelimab for approval;
    • funding: a 2023 sale of royalty rights to OMERS ($215M upfront), a 2024 share sale ($201.3M gross) and sales of Zenas shares received as licence payment ($66.9M in Q3 2026); Genentech ended its collaboration in September 2026.
  • How well it is working, in numbers:
    • partner milestones: $45.3M in 2025 and $39.0M in the first nine months of 2026 (10-Q, note 2);
    • XmAb819: tumours shrank in 5 of 11 evaluable patients (45.5%) at the chosen dose, with 5.9% of patients stopping treatment because of related side effects across the expansion cohorts (Q3 release);
    • own products: none on sale;
    • targets: year-end 2026 cash of $480–500M and a runway “into 2029”; no revenue or profit targets.
  • What to watch: see section 8.

8. What to watch

Last updated Nov 16, 2026. Reflects the 10-Q for Q3 2026, the Q3 2026 release (Nov 4, 2026) and the Nov 9 plamotamab and XmAb657 release.

Date Item Source
Around year-end 2026 XmAb942: blinded interim analysis (a mid-study review without revealing treatment assignments) of XENITH-UC in ulcerative colitis Q3 release
Not announced Q4 and full-year 2026 results; Xencor had not announced a date as of Nov 16, 2026 (it reported 2025 results on Feb 25, 2026) Feb 25 release
Q1 2027 XmAb657: enrolment of patients with severe autoimmune diseases to begin, after 30 healthy participants were dosed by Nov 1 Nov 9 release
1H 2027 XmAb819: more results at the chosen dose, results of under-the-skin dosing, and FDA talks on a potential accelerated approval; first XmAb412 data in healthy participants Q3 release
May 27, 2027 FDA target decision date for Zenas’ obexelimab Zenas release
Aug 2027 Second $52.5M Alexion payment due 8-K
2H 2027 XENITH-UC main result (12-week induction) Q3 release
By end of 2027 XmAb819 Phase 3 against tivozanib to start, subject to regulatory feedback Q3 release
Additional dates
Date Item Source
2027 XmAb541 with XmAb808 expected to reach the combination’s target dose range Q3 release

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 27, 2026$29.18 (Oct 26)$2.2B$1.7B†20.7×16.0×n/mn/m−29%−198%$486M†12 months to Jun 30, 2026
Nov 16, 2026$37.09 (Nov 13)$2.8B$2.2B†13.9×11.1×n/mn/m+34%−88%$556M†12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 4, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 27, 2026: † Debt excludes $104.9M of liabilities from the sale of future royalties, which the company reports separately. Nov 16, 2026: † Debt excludes $95.1M of liabilities from the sale of future royalties, which the company reports separately. Oct 27, 2026 row: Corrected Oct 30, 2026: cash and investments now include short-term marketable securities ($486 million, previously $153 million); net cash $381 million (previously $48 million), enterprise value $1.84 billion (previously $2.17 billion) and EV/sales 17.5× (previously 20.7×). Price and date unchanged. Corrected Oct 31, 2026: market value now uses common shares outstanding (74.4 million on the 10-Q cover page, Jul 31, 2026), our standard basis, instead of 76.0 million shares including pre-funded warrants; market value $2.2B (was $2.2B), with enterprise value and multiples recalculated. Price and date unchanged. Oct 27, 2026 row: Updated Nov 16, 2026: net cash is $486.4M, not $381.5M, and enterprise value $1,683M, not $1,788M (EV/sales 16.0×, not 17.0×). We had counted a $104.9M liability from the sale of future royalties as debt; it now stays out, as for other companies, because it is repaid from royalties rather than cash. Price, date and market value are unchanged. Nov 16, 2026 price: official close, Yahoo Finance, Nasdaq.

Notes and calculations

  1. 35.03 ÷ 30.64 − 1 (closes of Nov 4 and Nov 3, 2026). ↩

  2. Remaining ownership = 1% × 57.9M ÷ 76.5M; growth = (76.46 ÷ 57.87 − 1) × 100 ≈ 32%; annual growth = [(76.46 ÷ 57.87)^(1 ÷ 5.75) − 1] × 100 ≈ 5.0%. ↩

  3. [(8,093,712 × $18.00) + (3,088,888 × $17.99)] ÷ 11,182,600 = $17.9972, rounded to $18.00 ($201.3M ÷ 11.18M). ↩

  4. Stock pay ÷ revenue. ↩

  5. FY2025 − first nine months of 2025 + first nine months of 2026. ↩

  6. Operating cash flow + capital spending, shown as a negative cash outflow. ↩

  7. $555.69M ÷ ($70.21M × 4 = $280.85M a year) = 1.98 years. ↩

  8. Without removing one-off receipts: −$176.447M ÷ 4 = −$44.11M a quarter; $555.7M + $52.5M runs out in Q1 2030. ↩

  9. One-off receipts = $52.5M + $25.0M + $10.0M + $7.0M + $4.0M + $2.5M + $1.8M + $1.5M + $0.1M = $104.4M; they are 59% of the trailing free cash outflow of $176.4M. ↩

  10. Partner revenue ÷ total. Alexion plus Incyte: 56% + 41% = 97% in 2025; 71% + 7% = 78% in the first nine months of 2026 ($122.3M + $12.3M of $172.3M). ↩ ↩2

  11. The table above (10-K FY2025, note 2; 10-Q Q3 2026, note 2). ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Xencor: Website (external site)Investor relations (external site)SEC filings (external site)